PredictMedix (CSE: PMED) (OTCQB: PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally—the Company’s Safe Entry Stations – powered by a proprietary artificial intelligence (AI).
The technology uses multispectral cameras to analyze physiological data patterns and predict various health issues, including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue or various mental illnesses.
PredictMedix is peerless as a developer of technology that functions by identifying signs of impairment and correlating them with various levels of impairment-inducing agents. The patented technology will also be used in Predictmedix’s AI-powered mobile app, which works alongside a portable multispectral imaging camera for non-invasive impairment detection.
Hard to Believe PredictMedix Could be More Interesting to Investors. Well, Read On;
Using artificial intelligence technology, Predictmedix’s Safe Entry Stations already screen individuals for vital parameters such as temperature, heart rate, respiratory rate, and oxygen saturation. With the added ability to measure systolic and diastolic blood pressure, Safe Entry Stations now provide even greater accuracy for its healthcare applications as well as workplace and law enforcement screening tools.
The Company also announced the detection capability to identify non-invasive Heart Rate Variability, which is critical as an initial threshold to many diseases through the functionality of the parasympathetic and sympathetic nervous systems. Those are the two components of heart function.
Dr. Rahul Kushwah, Chief Operations Officer at Predictmedix, states, “With the addition of HRV, blood oxygen saturation, and blood pressure readings, Predictmedix’s Safe Entry Stations take us into a new frontier of what is possible for healthcare and other industries alike,” said Kushwah. “We’re proud to be at the forefront of AI-based screening solutions and are committed to continuing to provide innovative technology to help keep people safe and healthy.”
This announcement is like looking up ‘Big Deal’ in the Dictionary and seeing PredictMedix’s name as the definition. Imagine early detection of heart disease? Imagine no more. Did I mention this is a big deal for patients and Investors?
This type of technology could drastically reduce heart disease, which would no longer be a ‘Silent Killer.” High blood pressure is often called the “silent killer” because most people with it don’t have any symptoms. And that silence can be deadly. High blood pressure can lead to severe problems, including heart attack, heart failure and stroke. That’s why it’s essential to know your risk factors for developing high blood pressure — and to take steps to lower your risks. (Mayo Clinic).
Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives annually. And you can be sure, without technology such as PMEDs, that number will continue to rise.
Other Areas of Detection and Influence;
- PMED has several substantive and unique patents, both granted and pending.
- The Companies market is virtually limitless, with exceptional long-term growth prospects.
- Should have public acceptance when traded on against accidents and fatalities caused by impairment or fatigue.
- It provides a quick and viable way to detect illnesses such as COVID-19, potentially before the individual knows.
- No filing or storing of personal information.
- Insurance, risk, and underwriting companies will embrace. Technology in every car, truck etc.?
The Company’s detection time for identifying impairment or disease is less than 5 seconds. The next competitor that is even remotely close takes 20 minutes.
The Company’s Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict various health issues, including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue or various mental illnesses. Predictmedix’s proprietary remote patient care platform empowers medical professionals with AI-powered tools to improve patient health outcomes.
- Obvious cost savings are myriad to insured entities that use the tech, as up to 50% of workers’ compensation claims directly result from substance abuse.
- Few labour or ‘responsibility’ industries wouldn’t benefit from PMED’s patented tech. Think transportation, factory, building trades and care homes and on and on.
- The benefits for all involved—except those coming to work impaired—are obvious. Nice to know your pilot and co-pilot are sober.
Try to imagine a hospital, clinic, or doctor’s office that wouldn’t want this amazing technology: Go ahead. Try.
The shares –I own some– are trading at C$0.11 a share. Market cap C$14.5 million. Average daily volume abt 200k.
Have a look. Your heart will thank you.
